Abstract

The causative agent of the COVID-19 pandemic, SARS-CoV-2, is steadily mutating during continuous transmission among humans. Such mutations can occur in the spike (S) protein that binds to the ACE2 receptor and is cleaved by TMPRSS2. However, whether S mutations affect SARS-CoV-2 cell entry remains unknown. Here, we show that naturally occurring S mutations can reduce or enhance cell entry via ACE2 and TMPRSS2. A SARS-CoV-2 S-pseudotyped lentivirus exhibits substantially lower entry than that of SARS-CoV S. Among S variants, the D614G mutant shows the highest cell entry, as supported by structural and binding analyses. Nevertheless, the D614G mutation does not affect neutralization by antisera against prototypic viruses. Taken together, we conclude that the D614G mutation increases cell entry by acquiring higher affinity to ACE2 while maintaining neutralization susceptibility. Based on these findings, further worldwide surveillance is required to understand SARS-CoV-2 transmissibility among humans.

SARS-CoV-2 D614G spike protein mutation is one of the predominant circulating vital mutants. Here, Ozono et al. demonstrate that D614G mutation increases in vitro cell entry by acquiring higher affinity to ACE2.

Details

Title
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity
Author
Ozono Seiya 1   VIAFID ORCID Logo  ; Zhang Yanzhao 2 ; Ode Hirotaka 3   VIAFID ORCID Logo  ; Sano Kaori 2   VIAFID ORCID Logo  ; Tan, Toong Seng 4   VIAFID ORCID Logo  ; Imai Kazuo 5   VIAFID ORCID Logo  ; Miyoshi Kazuyasu 5   VIAFID ORCID Logo  ; Kishigami Satoshi 6   VIAFID ORCID Logo  ; Ueno Takamasa 7   VIAFID ORCID Logo  ; Iwatani Yasumasa 3   VIAFID ORCID Logo  ; Suzuki Tadaki 2   VIAFID ORCID Logo  ; Tokunaga Kenzo 2   VIAFID ORCID Logo 

 National Institute of Infectious Diseases, Department of Pathology, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880); University of Yamanashi, Faculty of Life and Environmental Sciences, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581) 
 National Institute of Infectious Diseases, Department of Pathology, Tokyo, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880) 
 National Hospital Organization Nagoya Medical Center, Clinical Research Center, Nagoya, Japan (GRID:grid.410840.9) (ISNI:0000 0004 0378 7902) 
 Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto, Japan (GRID:grid.410795.e) 
 Self-Defense Forces Central Hospital, Tokyo, Japan (GRID:grid.415474.7) 
 University of Yamanashi, Faculty of Life and Environmental Sciences, Yamanashi, Japan (GRID:grid.267500.6) (ISNI:0000 0001 0291 3581) 
 Joint Research Center for Human Retrovirus Infection, Division of Infection and Immunity, Kumamoto, Japan (GRID:grid.267500.6) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2487157750
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.